Asparaginase, a component of a multi-agent chemotherapeutic regimen for treatment of pediatric and adult patients with acute lymphoblastic leukemia (ALL), converts asparagine and glutamine to aspartate and glutamate, respectively, decreasing plasma concentrations of asparagine and glutamine [15]. This evidence concerns the gene ASPG and acute lymphoblastic leukemia.